US EditionRussian Claims mRNA Cancer Vaccine 'Enteromix' Achieves 100% Efficacy, Awaits Health Ministry Sign-Off
EnteroMix, a personalized mRNA vaccine targeting colorectal cancer, showed 100% safety and significant tumor reduction in 48 volunteer Phase I trials, pending Russian health approval.
- On Saturday, FMBA head Veronika Skvortsova announced EnteroMix, Russia's mRNA-based cancer vaccine by National Medical Research Radiological Centre and Engelhardt Institute, is ready for use and awaiting approval at the Eastern Economic Forum.
- After several years of work, developers focused three years on preclinical studies that confirmed safety and created personalised mRNA based on each patient's RNA, FMBA head Veronika Skvortsova said.
- Researchers reported tumour reductions of 60% to 80% in preclinical animal models and early human data, while the Phase I trial with around 48 volunteers showed very low toxicity and no serious side effects.
- Health authorities must grant approval before EnteroMix can reach patients, and experts urge larger Phase II and Phase III clinical trials to validate efficacy despite promising early safety data.
- Globally, developers in Britain and the United States are also racing to develop cancer vaccines; EnteroMix employs a novel approach using four re-engineered harmless viruses while BioNTech, Moderna, and Merck pursue vaccines targeting glioblastoma and ocular melanoma.
43 Articles
43 Articles
Russia Set To Launch Personalized mRNA Cancer Vaccine * 100PercentFedUp.com * by Danielle
Russia is creating a personalized mRNA cancer vaccine and intends to begin treating patients in October 2025. The vaccine, EnteroMix, was developed using technology similar to that of the COVID-19 mRNA vaccines. “The vaccine uses AI-driven algorithms to create individualized mRNA blueprints based on patient genetic data, reducing development time from months to hours,” MedPath stated. “The Russian EnteroMix cancer vaccine is now ready for clinic…
Is Russia’s cancer vaccine ready for use?
Scientists in Russia have developed an mRNA-based cancer vaccine, which has reportedly shown 100 per cent efficacy during clinical trials. The vaccine, called Enteromix, now reportedly awaits final approval from the Ministry of Health before being available to the public
Russia's Enteromix Cancer Vaccine Shows 100% Efficacy In Early Trials
Russian Mrna Vaccine Cancer: Enteromix, has achieved 100% efficacy and safety in early clinical trials targeting colorectal cancer. Developed using COVID-19 vaccine technology, it's now awaiting regulatory approval.
Coverage Details
Bias Distribution
- 63% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
